Data completeness
0/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLUIDIL (cyclothiazide) is an oral thiazide diuretic tablet indicated for hypertension and edema management. It works by inhibiting sodium reabsorption in the distal convoluted tubule, promoting urinary sodium and water excretion to reduce blood volume and lower blood pressure. Cyclothiazide is a potent, short-acting thiazide with rapid onset suitable for acute fluid management.
Pre-Launch
Early-stage launch opportunity with Pfizer backing; commercial team building and market preparation underway with potential for growth in hypertension/edema segments.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FLUIDIL represents a pre-launch opportunity within Pfizer's cardiovascular portfolio, offering entry-level and mid-career roles in brand establishment, market access, and field force deployment. Working on a legacy-mechanism relaunch requires strategy differentiation and competitive positioning in a mature therapeutic class.
Brand ManagerField Sales Representative
Worked on FLUIDIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.